Home | Site Map | Contact Us | Bookmark
 
  Single Disease Educational Content
  Multi-Disease
Educational Content
  Other Resources
  About CLDF
 
 

Hepatocellular Carcinoma (HCC)
  Additional content on this specific disease state can be found in the:     Click on another disease specific
area listed above to view content
 

Liver News Library
 
 
  
         
  Diagnosis and Management of
Hepatocellular Carcinoma: 2009 Update		  
  Target Audience  
  This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, physician assistants, and nurse practitioners involved in the management of chronic liver disease.  
  Goal Statement  
  To provide important clinical data on the management of hepatocellular carcinoma (HCC)  
  Educational Objectives  
  Upon completion of this activity, participants should be better able to:  
  Credit Designation   • Review the epidemiology and etiology of HCC  
  1.0 AMA PRA
Category 1 Credit(s)™		   • Describe the latest treatment advances  
    • Discuss the latest treatment algorithms for the
  management of HCC 		 
 

 Download
Accreditation Statement  
  Please see page 1 of the monograph for full accreditation statement.  
Jointly sponsored by Purdue University School of Pharmacy and the Chronic Liver Disease Foundation.
This educational material was supported by grants from Bayer Healthcare LLC and Onyx Pharmaceuticals.
 
       

  

Hepatology 2009 Current Perspectives on Chronic Liver Disease   Educational Webcast
       

  

Current Perspectives on Hepatocellular Carcinoma   Educational Webcast
  Presented by: Myron Tong, MD    
 
 
HCC 2010
New Advances in the Management of Hepatocellular Carcinoma (HCC)
 
 

HCC Slide Archive

  
 
HCC 2009
Hepatocellular Carcinoma  
 
 
HCC 2008
Hepatocellular Carcinoma
 
  1. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma
    Minami Y, Kudo M. World J Gastroenterol. 2011 Dec 7;17(45):4952-9.

  2. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines
    Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. J Hepatol. 2011 Dec 12. [Epub ahead of print]

  3. Targeting Liver Cancer: First Steps toward a miRacle?
    Schwabe RF, Wang TC. Cancer Cell. 2011 Dec 13;20(6):698-9.

  4. A Meta-Analysis of Array-CGH Studies Implicates Antiviral Immunity Pathways in the Development of Hepatocellular Carcinoma
    Guo X, Yanna, Ma X, An J, Shang Y, Huang Q, Yang H, Chen Z, Xing J. PLoS One. 2011;6(12):e28404. Epub 2011 Dec 12.

  5. Number and Tumor Size Are Not Sufficient Criteria to Select Patients for Liver Transplantation for Hepatocellular Carcinoma
    Piardi T, Gheza F, Ellero B, Woehl-Jaegle ML, Ntourakis D, Cantu M, Marzano E, Audet M, Wolf P, Pessaux P. Ann Surg Oncol. 2011 Dec 17. [Epub ahead of print]

  6. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma
    Wu TH, Yu MC, Chen TC, Lee CF, Chan KM, Wu TJ, Chou HS, Lee WC, Chen MF. J Surg Oncol. 2012 Jan;105(1):85-90. doi: 10.1002/jso.22060.

  7. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma
    Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok TS, Yeo W. Cancer. 2011 Dec 16. doi: 10.1002/cncr.26726. [Epub ahead of print]

  8. Multimodality Treatment with Conventional Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma
    Ashoori N, Paprottka P, Trumm C, Bamberg F, Kolligs FT, Rentsch M, Reiser MF, Jakobs TF. Digestion. 2011 Dec 8;85(1):18-26. [Epub ahead of print]

  9. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma
    Zhong JH, Li le Q, Wu LC. Cochrane Database Syst Rev. 2011 Dec 7;12:CD008713.

  10. Beyond
    Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Nakanuma Y, Paradis V, Quaglia A, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ. Am J Clin Pathol. 2012 Jan;137(1):5-9.

  11. Effects of risk factors and ki-67 on rates of recurrence on patients who have undergone liver transplant for hepatocellular carcinoma
    Aktas S, Karakayali H, Moray G, Ozdemir H, Haberal M. Transplant Proc. 2011 Dec;43(10):3807-12.

  12. Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation
    Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Int J Radiat Oncol Biol Phys. 2011 Dec 13. [Epub ahead of print]

  13. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled
    Matsuda Y, Fukumoto M. Med Mol Morphol. 2011 Dec;44(4):183-9. Epub 2011 Dec 17.

  14. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis
    Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. J Cancer Res Clin Oncol. 2011 Dec 18. [Epub ahead of print]

  15. Rate of Tumor Growth Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation in Patients Beyond Milan or UCSF Criteria
    Hanouneh IA, Macaron C, Lopez R, Aucejo F, Zein NN. Transplant Proc. 2011 Dec;43(10):3813-8.

  16. The molecular pathogenesis and clinical implications of hepatocellular carcinoma
    Meguro M, Mizuguchi T, Kawamoto M, Hirata K. Int J Hepatol. 2011;2011:818672. Epub 2011 Dec 4.

  17. Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models
    Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Radiology. 2011 Dec 20. [Epub ahead of print]

  18. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation
    Lai Q, Avolio AW, Manzia TM, Sorge R, Agnes S, Tisone G, Berloco PB, Rossi M. Clin Transplant. 2011 Dec 22. doi: 10.1111/j.1399-0012.2011.01572.x. [Epub ahead of print]

  19. Utilization and Outcomes of Palliative Therapy for Hepatocellular Carcinoma: A Population-based Study in the United States
    Davila JA, Duan Z, McGlynn KA, El-Serag HB. J Clin Gastroenterol. 2012 Jan;46(1):71-7.

  20. Adverse Outcomes in Patients with Postoperative Ascites after Liver Resection for Hepatocellular Carcinoma
    Chan KM, Lee CF, Wu TJ, Chou HS, Yu MC, Lee WC, Chen MF. World J Surg. 2011 Dec 1. [Epub ahead of print]

  21. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? NO
    Heuman DM, Gilles HS, Solomon C, Bajaj JS. Eur J Intern Med. 2012 Jan;23(1):37-9. Epub 2011 Nov 4.

  22. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? Yes.
    Parisi G. Eur J Intern Med. 2012 Jan;23(1):34-6. Epub 2011 Nov 26.

  23. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy
    Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Wu JC, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD. Clin Radiol. 2011 Dec 6. [Epub ahead of print]

  24. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated?
    Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. World J Gastroenterol. 2011 Dec 14;17(46):5083-8.

  25. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation
    Kohli V, Singhal A, Elliott L, Jalil S. Transpl Int. 2011 Dec 12. doi: 10.1111/j.1432-2277.2011.01396.x. [Epub ahead of print]

  26. Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial
    Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Radiology. 2011 Dec 12. [Epub ahead of print]

  27. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy
    Lencioni R. Crit Rev Oncol Hematol. 2011 Dec 3. [Epub ahead of print]

  28. Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
    Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Am J Gastroenterol. 2011 Dec 13. doi: 10.1038/ajg.2011.425. [Epub ahead of print]

  29. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-coinfected patients: Results from ANRS CO13 HEPAVIH
    Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. J Hepatol. 2011 Dec 12. [Epub ahead of print]

  30. Liver resection for hepatocellular carcinoma: case-matched analysis of laparoscopic versus open resection
    Kim HH, Park EK, Seoung JS, Hur YH, Koh YS, Kim JC, Cho CK, Kim HJ. J Korean Surg Soc. 2011 Jun;80(6):412-9. Epub 2011 Jun 9.

  31. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: Biopsy for all, some, or none?
    Khalili K, Kyoung Kim T, Jang HJ, Kochak Yazdi L, Guindi M, Sherman M. Hepatology. 2011 Sep 2. doi: 10.1002/hep.24638. [Epub ahead of print]

  32. Multidisciplinary Management of Hepatocellular Carcinoma
    Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Clin Gastroenterol Hepatol. 2011 Nov 11. [Epub ahead of print]

  33. Anti-inflammatory drugs reduce the risk of hepatocellular carcinoma development
    Rino Y, Tarao K.ISRN Oncol. 2011;2011:390676. Epub 2011 Jul 7.

  34. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma
    Unek T, Karademir S, Arslan NC, Egeli T, Atasoy G, Sagol O, Obuz F, Akarsu M, Astarcioglu I. World J Gastroenterol. 2011 Oct 7;17(37):4206-12.

  35. HCC, diet and metabolic factors: Diet and HCC
    Montella M, Crispo A, Giudice A. Hepat Mon. 2011 Mar 1;11(3):159-162.

  36. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling
    Yang JD, Seol SY, Leem SH, Kim YH, Sun Z, Lee JS, Thorgeirsson SS, Chu IS, Roberts LR, Kang KJ. J Korean Med Sci. 2011 Nov;26(11):1428-38. Epub 2011 Oct 27.

  37. Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma
    Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, Welker M, Shi Y, Peveling-Oberhag J, Polta A, von Wagner M, Radeke HH, Sarrazin C, Trojan J, Zeuzem S, Kronenberger B, Piiper A. PLoS One. 2011;6(10):e26971. Epub 2011 Oct 31.

  38. Genetic variants in HLA-DP/DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development
    Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24799. [Epub ahead of print]

  39. Non-alcoholic steatohepatitis: new insights from OMICS studies
    Cécile M, Davide DE, Antonin B, Catherine B, Antoinette L. Curr Pharm Biotechnol. 2011 Nov 25. [Epub ahead of print]

  40. Resection for Hepatocellular Carcinoma: Is it justifiable to restrict this to the AASLD/BCLC criteria?
    Chow PK. J Gastroenterol Hepatol. 2011 Dec 6. doi: 10.1111/j.1440-1746.2011.07034.x. [Epub ahead of print]

  41. Liver resection after downstaging hepatocellular carcinoma with sorafenib
    Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Int J Hepatol. 2011;2011:791013. Epub 2011 Mar 20.

  42. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis
    Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Hepatology. 2011 Dec 2. doi: 10.1002/hep.25512. [Epub ahead of print]

  43. The Outcomes and Safety of Single-Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)
    Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, Cheung TT, Chan AC, Pang RW, Poon R, Fan ST, Yau T. Oncologist. 2011 Dec 1. [Epub ahead of print]

  44. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma
    Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura SI, Shiraha H, Kuwaki K, Hagihara H, Ikeda F, Miyake Y, Takaki A, Yamamoto K. J Gastroenterol. 2011 Nov 3. [Epub ahead of print]

  45. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
    Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R; The HCC Working Group. Expert Rev Anticancer Ther. 2011 Aug 26. [Epub ahead of print]

  46. Type 2 Diabetes and hepatocellular carcinoma: A Case-control study in patients with chronic hepatitis B
    Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N. Int J Cancer. 2011 Nov 2. doi: 10.1002/ijc.27337. [Epub ahead of print]

  47. Clinicopathologic Features and Risk Factors for Extrahepatic Recurrences of Hepatocellular Carcinoma After Curative Resection
    Ochiai T, Ikoma H, Okamoto K, Kokuba Y, Sonoyama T, Otsuji E. World J Surg. 2011 Nov 4. [Epub ahead of print]

  48. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; on behalf of the OLT for HCC Consensus Group. Lancet Oncol. 2011 Oct 31. [Epub ahead of print]

  49. Stage of hepatocellular carcinoma is associated with periodontitis
    Tamaki N, Takaki A, Tomofuji T, Endo Y, Kasuyama K, Ekuni D, Yasunaka T, Yamamoto K, Morita M. J Clin Periodontol. 2011 Nov;38(11):1015-20. doi: 10.1111/j.1600-051X.2011.01777.x. Epub 2011 Sep 15.

  50. Postoperative infectious and non-infectious complications after hepatectomy for hepatocellular carcinoma
    Kaibori M, Ishizaki M, Matsui K, Kwon AH. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1747-56. doi: 10.5754/hge10533.

  51. Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment
    Toro A, Pulvirenti E, Palermo F, Di Carlo I. Surg Oncol. 2011 Nov 18. [Epub ahead of print]

  52. Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
    Shao YY, Chen PJ, Lin ZZ, Huang CC, Ding YH, Lee YH, Hsu CH, Cheng AL. Anticancer Res. 2011 Nov;31(11):4007-11.

  53. MRI features of hepatocellular carcinoma expressing progenitor cell markers
    Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Hepatology. 2011 Nov 16. doi: 10.1002/hep.24794. [Epub ahead of print]

  54. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma
    Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. World J Gastroenterol. 2011 Oct 14;17(38):4258-70.

  55. PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection
    Noda T, Yamamoto H, Takemasa I, Yamada D, Uemura M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Liver Int. 2011 Aug 11. doi: 10.1111/j.1478-3231.2011.02619.x. [Epub ahead of print]

  56. MRI features of hepatocellular carcinoma expressing progenitor cell markers
    Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS. Liver Int. 2011 Sep 13. doi: 10.1111/j.1478-3231.2011.02640.x. [Epub ahead of print]

  57. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
    Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T. J Gastroenterol. 2011 Nov 23. [Epub ahead of print]

  58. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma
    Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24813. [Epub ahead of print]

  59. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
    He J, Zeng ZC, Fan J, Zhou J, Sun J, Chen B, Yang P, Wang BL, Zhang BH, Zhang JY. BMC Cancer. 2011 Nov 22;11(1):492. [Epub ahead of print]

  60. Subtle Hepatocellular Carcinoma: A Persisting Role for Alpha-Fetoprotein Monitoring in High-Risk Patients with Cirrhosis
    Schlansky B, Dobos N, Zaman A. Case Rep Gastroenterol. 2011 Sep;5(3):565-568. Epub 2011 Oct 1.

  61. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?
    Berry K, Ioannou GN. Am J Transplant. 2011 Nov 28. doi: 10.1111/j.1600-6143.2011.03853.x. [Epub ahead of print]

  62. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
    Farinati F, Giacomin A, Vanin V, Sergio A, Burra P, Cillo U, Di Nolfo A, Del Poggio P, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Cazzagon N, Rapaccini GL, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Eur J Gastroenterol Hepatol. 2011 Nov 18. [Epub ahead of print]

  63. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
    Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F. Invest New Drugs. 2011 Oct 29. [Epub ahead of print]

  64. Hepatitis B and C Virus Infection and Hepatocellular Carcinoma in China: A Review of Epidemiology and Control Measures
    Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. J Epidemiol. 2011 Oct 22. [Epub ahead of print]

  65. Diagnostic and prognostic molecular markers in hepatocellular carcinoma
    Mínguez B, Lachenmayer A. Dis Markers. 2011 Jan 1;31(3):181-90.

  66. Limited Liver Resection: A Good Indication for the Treatment of Hepatocellular Carcinoma in Elderly Patients
    Portolani N, Baiocchi GL, Coniglio A, Tiberio GA, Prestini K, Gheza F, Benetti A, Maria Giulini S. Jpn J Clin Oncol. 2011 Oct 28. [Epub ahead of print]

  67. From liver cirrhosis to HCC
    Bolondi L, Gramantieri L. Intern Emerg Med. 2011 Oct;6 Suppl 1:93-8.

  68. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?
    Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. J Huazhong Univ Sci Technolog Med Sci. 2011 Oct;31(5):637-41. Epub 2011 Oct 25.

  69. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: Chemoembolization and stent combined with iodine-125 seed
    Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. Cancer Biol Ther. 2011 Nov 15;12(10). [Epub ahead of print]

  70. Follow-Up of High-Intensity Focused Ultrasound Treatment for Patients with Hepatocellular Carcinoma
    Xu G, Luo G, He L, Li J, Shan H, Zhang R, Li Y, Gao X, Lin S, Wang G. Ultrasound Med Biol. 2011 Oct 26. [Epub ahead of print]

  71. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal
    Nobili V, Sanyal AJ. J Gastroenterol. 2011 Oct 8. [Epub ahead of print]

  72. MWA Combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma
    Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. Int J Hyperthermia. 2011 Oct 3. [Epub ahead of print]

  73. Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma
    Okamura Y, Maeda A, Matsunaga K, Kanemoto H, Uesaka K. J Hepatobiliary Pancreat Sci. 2011 Oct 8. [Epub ahead of print]

  74. Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma
    Antoch G, Roelle G, Ladd SC, Kuehl H, Heusner TA, Sotiropoulos GC, Hilgard P, Forsting M, Verhagen R. Eur J Radiol. 2011 Oct 4. [Epub ahead of print]

  75. Comparative Analysis of the Safety and Efficacy of Transcatheter Arterial Chemoembolization and Yttrium-90 Radioembolization in Patients with Unresectable Hepatocellular Carcinoma
    Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. J Vasc Interv Radiol. 2011 Oct 7. [Epub ahead of print]

  76. AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature
    Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA. Onkologie. 2011;34(10):538-42. Epub 2011 Sep 16.

  77. High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy
    Shao YY, Lin ZZ, Chen TJ, Hsu C, Shen YC, Hsu CH, Cheng AL. Oncology. 2011 Oct 4;81(2):98-103. [Epub ahead of print]

  78. Radiofrequency ablation for the treatment of hepatocellular carcinoma with decompensated cirrhosis
    Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Oncology. 2011;81(1):39-44. Epub 2011 Sep 9.

  79. Sorafenib in hepatocellular carcinoma - a post marketing evaluation
    Trojniak MP, Palozzo AC, Mazurek M, Jirillo A. Immunopharmacol Immunotoxicol. 2011 Oct 8. [Epub ahead of print]

  80. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma
    Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Liver Transpl. 2011 Oct;17 Suppl 2:S6-S13. doi: 10.1002/lt.22423.

  81. Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: A meta-analysis
    Li N, Wu YR, Wu B, Lu MQ. Hepatol Res. 2011 Oct 11. doi: 10.1111/j.1872-034X.2011.00890.x. [Epub ahead of print]

  82. Long-Term Outcome of Percutaneous Ablation in Very Early-Stage Hepatocellular Carcinoma
    Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, Liu GJ, Lu MD. J Gastrointest Surg. 2011 Oct 5. [Epub ahead of print]

  83. Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma
    Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Am J Gastroenterol. 2011 Oct 18. doi: 10.1038/ajg.2011.327. [Epub ahead of print]

  84. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study
    Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, Onishi H, Nakamura S, Yamamoto K, Shimizu K. J Gastroenterol Hepatol. 2011 Oct 17. doi: 10.1111/j.1440-1746.2011.06948.x. [Epub ahead of print]

  85. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
    Landman MP, Feurer ID, Pinson CW, Moore DE. HPB (Oxford). 2011 Nov;13(11):783-91. doi: 10.1111/j.1477-2574.2011.00355.x. Epub 2011 Aug 19.

  86. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review
    Tan CH, Low SC, Thng CH. Int J Hepatol. 2011;2011:519783. Epub 2011 Apr 19.

  87. Chemoembolization for intermediate HCC: Is there proof of survival benefit?
    Forner A, Llovet JM, Bruix J. J Hepatol. 2011 Oct 15. [Epub ahead of print]

  88. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma
    Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K. J Gastroenterol Hepatol. 2011 Nov;26(11):1604-11. doi: 10.1111/j.1440-1746.2011.06887.x.

  89. Radiofrequency ablation of hepatocellular carcinoma: a literature review
    Minami Y, Kudo M. Int J Hepatol. 2011;2011:104685. Epub 2011 May 11.

  90. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: A meta-analysis
    Li L, Zhang J, Liu X, Li X, Jiao B, Kang T. J Gastroenterol Hepatol. 2011 Oct 17. doi: 10.1111/j.1440-1746.2011.06947.x. [Epub ahead of print]

  91. Early Hepatocellular Carcinoma: Transplantation versus Resection: The Case for Liver Resection
    Merchant N, David CS, Cunningham SC. Int J Hepatol. 2011;2011:142085. Epub 2011 Apr 27.

  92. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
    Schattenberg JM, Schuppan D. Curr Opin Lipidol. 2011 Oct 14. [Epub ahead of print]

  93. Effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
    Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. Aliment Pharmacol Ther. 2011 Oct 27. doi: 10.1111/j.1365-2036.2011.04896.x. [Epub ahead of print]

  94. Liver transplantation for hepatocellular carcinoma: lessons learned and future directions
    Levi DM, Nishida S. Clin Liver Dis. 2011 Nov;15(4):717-25.

  95. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis
    Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, Wen TF, Xu MQ, Wang WT, Yang JY. World J Gastroenterol. 2011 Sep 14;17(34):3941-7.

  96. Increased HCMV seroprevalence in patients with hepatocellular carcinoma
    Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Virol J. 2011 Oct 27;8(1):485. [Epub ahead of print]

  97. The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma
    Ponziani F, Ojetti V, Tortora A, Di Maurizio L, Purchiaroni F, Gasbarrini A. Expert Opin Drug Metab Toxicol. 2011 Oct 27. [Epub ahead of print]

  98. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J. World J Gastroenterol. 2011 Sep 14;17(34):3922-32.

  99. Screening for hepatocellular carcinoma
    Lui HF. Int J Hepatol. 2011;2011:363151. Epub 2011 Oct 17.

  100. Non-alcoholic fatty liver disease: is iron relevant?
    O'Brien J, Powell LW. Hepatol Int. 2011 Aug 12. [Epub ahead of print]

  101. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients
    Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Antivir Ther. 2011;16(7):959-68.

  102. RPL36 as a prognostic marker in hepatocellular carcinoma
    Song MJ, Jung CK, Park CH, Hur W, Choi JE, Bae SH, Choi JY, Choi SW, Han NI, Yoon SK. Pathol Int. 2011 Nov;61(11):638-44. doi: 10.1111/j.1440-1827.2011.02716.x. Epub 2011 Sep 23.

  103. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence
    Toso C, Mentha G, Majno P. Am J Transplant. 2011 Oct;11(10):2031-5. doi: 10.1111/j.1600-6143.2011.03689.x. Epub 2011 Aug 10.

  104. Epidemiology of the metabolic syndrome in the USA
    McCullough AJ. J Dig Dis. 2011 Oct;12(5):333-40. doi: 10.1111/j.1751-2980.2010.00469.x.

  105. Identification of osteopontin as a novel marker for early hepatocellular carcinoma
    Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Hepatology. 2011 Sep 27. doi: 10.1002/hep.24703. [Epub ahead of print]

  106. Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma
    Cheng CH, Lee CF, Wu TH, Chan KM, Chou HS, Wu TJ, Yu MC, Chen TC, Lee WC, Chen MF. World J Surg Oncol. 2011 Sep 30;9(1):114. [Epub ahead of print]

  107. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
    Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P. Aliment Pharmacol Ther. 2011 Sep 29. doi: 10.1111/j.1365-2036.2011.04860.x. [Epub ahead of print]

  108. Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD Era
    Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Dig Dis Sci. 2011 Sep 28. [Epub ahead of print]

  109. Hepatocellular carcinoma confirmation, treatment, and survival in SEER registries, 1992-2008
    Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatology. 2011 Sep 27. doi: 10.1002/hep.24710. [Epub ahead of print]

  110. Hepatocellular Carcinoma
    Hashem B. El-Serag, M.D., M.P.H. N Engl J Med 2011; 365:1118-1127September 22, 2011

  111. Genomic risk of hepatitis C-related hepatocellular carcinoma
    Hoshida Y, Fuchs BC, Tanabe KK. J Hepatol. 2011 Sep 27. [Epub ahead of print]

  112. Hepatocellular carcinoma, a rapidly increasing public health problem: the Tulane experience 2003-2009
    Tangutur NK, Medvedev SF, Regenstein F, Balart LA. J La State Med Soc. 2011 Jul-Aug;163(4):185-90.

  113. Efficacy and safety of sorafenib in combination with mTOR inhibitors in recurrent hepatocarcinoma after liver transplant
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Liver Transpl. 2011 Sep 19. doi: 10.1002/lt.22434. [Epub ahead of print]

  114. Smoking as an independent risk factor for hepatocellular carcinoma: the Singapore Chinese Health Study
    Koh WP, Robien K, Wang R, Govindarajan S, Yuan JM, Yu MC. Br J Cancer. 2011 Sep 13. doi: 10.1038/bjc.2011.360. [Epub ahead of print]

  115. Cancer preventive effect of pegylated interferon ?-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis
    Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Hepatol Res. 2011 Oct;41(10):955-964. doi: 10.1111/j.1872-034X.2011.00847.x. Epub 2011 Jun 28.

  116. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors
    Song T, Zhang W, Wu Q, Kong D, Ma W. Eur J Gastroenterol Hepatol. 2011 Sep 21. [Epub ahead of print]

  117. Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis
    Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT, Loong CC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. Ann Surg Oncol. 2011 Sep 13. [Epub ahead of print]

  118. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis
    Akima T, Tamano M, Hiraishi H. Hepatol Res. 2011 Oct;41(10):965-70. doi: 10.1111/j.1872-034X.2011.00846.x. Epub 2011 Aug 24.

  119. Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy
    Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. J Clin Gastroenterol. 2011 Sep 19. [Epub ahead of print]

  120. Chronic liver disease in the Hispanic population of the United States
    Carrion AF, Ghanta R, Carrasquillo O, Martin P. Clin Gastroenterol Hepatol. 2011 Oct;9(10):834-41. Epub 2011 May 12.

  121. Risk Factors of Ascites after Hepatectomy for Patients with Hepatocellular Carcinoma and Hepatitis B Virus-Associated Cirrhosis
    Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Hepatogastroenterology. 2011 Aug 10;59(113). doi: 10.5754/hge11399. [Epub ahead of print]

  122. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation
    Chen TM, Lin CC, Huang PT, Wen CF. J Gastroenterol Hepatol. 2011 Sep 13. doi: 10.1111/j.1440-1746.2011.06910.x. [Epub ahead of print]

  123. Conclusions: High baseline NLR was associated with worse OS for patients with early HCC; post-RFA NLR predicted not only OS, but also tumor recurrence.
    Hashimoto E, Tokushige K. Hepatol Res. 2011 Sep 15. doi: 10.1111/j.1872-034X.2011.00872.x. [Epub ahead of print]

  124. A clinicopathological model to predict bone metastasis in hepatocellular carcinoma
    Xiang ZL, Zeng ZC, Fan J, Wu WZ, He J, Zeng HY, Tang ZY. J Cancer Res Clin Oncol. 2011 Sep 14. [Epub ahead of print]

  125. MELD Exceptions and Rates of Waiting List Outcomes
    Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, Gheorghian A, Salvalaggio PR, Segev DL. Am J Transplant. 2011 Sep 15. doi: 10.1111/j.1600-6143.2011.03735.x. [Epub ahead of print]

  126. Frequency of Elevated Hepatocellular Carcinoma (HCC) Biomarkers in Patients With Advanced Hepatitis C
    Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Am J Gastroenterol. 2011 Sep 20. doi: 10.1038/ajg.2011.312. [Epub ahead of print]

  127. Critical Appraisal of Clinical Practice Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]

  128. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma with Decompensated Cirrhosis
    Wakuta A, Nouso K, Kariyama K, Nishimura M, Kishida M, Wada N, Mizushima T, Higashi T, Tanimoto M. Oncology. 2011 Sep 9;81(1):39-44. [Epub ahead of print]

  129. Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
    van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, Knegt RE, Mauser-Bunschoten E, van Erpecum K. Ann Hepatol. 2011 Oct 1;10(4):469-76.

  130. Hepatocellular carcinoma: clinical and radiological findings in patients with chronic B viral hepatitis and chronic C viral hepatitis
    Kim KE, Park MS, Bentley-Hibbert S, Baek SE, Kim YC, Kim MJ, Kim KW, Auh YH. Abdom Imaging. 2011 Sep 11. [Epub ahead of print]

  131. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports
    Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Wakabayashi G. Transplant Proc. 2011 Sep;43(7):2800-5.

  132. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. J Clin Oncol. 2011 Sep 12. [Epub ahead of print]

  133. Impact of Fibroscan® on management of chronic viral hepatitis in clinical practice
    van de Putte DF, Blom R, van Soest H, Mundt M, Verveer C, Arends J, Knegt RE, Mauser-Bunschoten E, van Erpecum K. Ann Hepatol. 2011 Oct 1;10(4):469-76.

  134. Hepatocellular carcinoma: clinical and radiological findings in patients with chronic B viral hepatitis and chronic C viral hepatitis
    Kim KE, Park MS, Bentley-Hibbert S, Baek SE, Kim YC, Kim MJ, Kim KW, Auh YH. Abdom Imaging. 2011 Sep 11. [Epub ahead of print]

  135. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation-interactions between calcineurin inhibitor: two case reports
    Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M, Wakabayashi G. Transplant Proc. 2011 Sep;43(7):2800-5.

  136. Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. J Clin Oncol. 2011 Sep 12. [Epub ahead of print]

  137. Critical Appraisal of Clinical Practice Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]

  138. Long-Term Outcomes After Resection Versus Transplantation for Hepatocellular Carcinoma Within UCSF Criteria
    Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Ann Surg Oncol. 2011 Aug 31. [Epub ahead of print]

  139. Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma
    Massarweh NN, Park JO, Bruix J, Yeung RS, Etzioni RB, Symons RG, Baldwin LM, Flum DR. J Oncol Pract. 2011 May;7(3):155-60.

  140. The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
    Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT. Oncologist. 2011 Sep 1. [Epub ahead of print]

  141. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
    Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Aliment Pharmacol Ther. 2011 Aug 24. doi: 10.1111/j.1365-2036.2011.04823.x. [Epub ahead of print]

  142. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria
    Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y, Shimomura H, Yamamoto H. J Gastroenterol Hepatol. 2011 Sep;26(9):1417-24. doi: 10.1111/j.1440-1746.2011.06775.x.

  143. Hepatoceclullar Carcinoma and Vitamin D- A review
    Chiang KC, Yeh CN, Chen MF, Chen TC. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06892.x. [Epub ahead of print]

  144. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis
    Akima T, Tamano M, Hiraishi H. Hepatol Res. 2011 Aug 24. doi: 10.1111/j.1872-034X.2011.00846.x. [Epub ahead of print]

  145. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma
    Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma

  146. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C
    Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y. Cancer Epidemiol Biomarkers Prev. 2011 Aug 29. [Epub ahead of print]

  147. CONCLUSIONS: Higher plasma ADAMTS13 activity and antigen level was a risk of HCC development in chronic liver disease.Impact:Plasma ADAMTS13 as a potential marker of hepatic stellate cells may be useful in the prediction of hepatocarcinogenesis.
    Schmidt S, Follmann M, Malek N, Manns MP, Greten TF. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06891.x. [Epub ahead of print]

  148. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial
    Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Oncol Rep. 2011 Aug 24. doi: 10.3892/or.2011.1433. [Epub ahead of print]

  149. Highly sensitive lens culinaris agglutinin-reactive ?-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease
    Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari SI, Saishoji A, Kure T, Ohno K, Toyokura E, Imanaka D, Moriuchi A, Uto H, Oketani M, Hashiguchi T, Tsubouchi H. Oncol Rep. 2011 Aug 19. doi: 10.3892/or.2011.1425. [Epub ahead of print]

  150. Hepatitis B virus and hepatocellular carcinoma at the miRNA level
    Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, Liang Z. World J Gastroenterol. 2011 Jul 28;17(28):3353-8.

  151. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma
    Huang L, Li J, Lau WY, Yan J, Zhou F, Liu C, Zhang X, Shen J, Wu M, Yan Y. J Gastroenterol Hepatol. 2011 Aug 22. doi: 10.1111/j.1440-1746.2011.06888.x. [Epub ahead of print]

  152. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma
    Kudo M. Dig Dis. 2011;29(3):289-302. Epub 2011 Aug 9.

  153. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy
    Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Morelli MC, Ravaioli M, Pinna AD. Liver Transpl. 2011 Aug 11. doi: 10.1002/lt.22397. [Epub ahead of print]

  154. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation
    Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y. J Gastroenterol. 2011 Aug 16. [Epub ahead of print]

  155. Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence
    Toso C, Mentha G, Majno P. Am J Transplant. 2011 Aug 10. doi: 10.1111/j.1600-6143.2011.03689.x. [Epub ahead of print]

  156. Viral Load, Genotypes, and Mutants in Hepatitis B Virus-Related Hepatocellular Carcinoma: Special Emphasis on Patients with Early Hepatocellular Carcinoma
    Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF. Dig Dis Sci. 2011 Aug 12. [Epub ahead of print]

  157. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient
    Nissen NN, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, Fair JH, Klein AS, Boland B, Colquhoun SD. HPB (Oxford). 2011 Sep;13(9):626-32. doi: 10.1111/j.1477-2574.2011.00342.x. Epub 2011 Jul 19.

  158. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma
    Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Eur J Cancer. 2011 Aug 9. [Epub ahead of print]

  159. Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C
    Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T. Cancer Manag Res. 2011;3:267-72. Epub 2011 Jul 28.

  160. Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma
    Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. J Vasc Interv Radiol. 2011 Aug 15. [Epub ahead of print]

  161. Repeat treatment for recurrent hepatocellular carcinoma: is it validated?
    Kishi Y, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguchi T. Langenbecks Arch Surg. 2011 Aug 17. [Epub ahead of print]

  162. Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C
    Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ. J Clin Oncol. 2011 Aug 22. [Epub ahead of print]

  163. mTOR Inhibitor for the Treatment of Hepatocellular Carcinoma
    Kudo M. Dig Dis. 2011;29(3):310-5. Epub 2011 Aug 9.

  164. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults
    Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, Edlinger M, Stocks T, Nagel G, Manjer J, Engeland A, Selmer R, Häggström C, Tretli S, Concin H, Jonsson H, Stattin P, Ulmer H. Int J Cancer. 2011 Jul 29. doi: 10.1002/ijc.26338. [Epub ahead of print]

  165. Management of patients with hepatocellular carcinoma and extrahepatic metastasis
    Lee HS. Dig Dis. 2011;29(3):333-8. Epub 2011 Aug 9.

  166. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials
    Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Med Sci Monit. 2011 Aug 1;17(8):RA169-176.

  167. Hepatocellular Carcinoma Screening Rates Vary by Etiology of Cirrhosis and Involvement of Gastrointestinal Sub-specialists
    Patwardhan V, Paul S, Corey KE, Mazhar SM, Richter JM, Thiim M, Chung RT. Dig Dis Sci. 2011 Jul 30. [Epub ahead of print]

  168. Radiofrequency ablation of high grade dysplastic nodules
    Cho YK, Chung JW, Kim Y, Cho HJ, Yang SH. Hepatology. 2011 Aug 1. doi: 10.1002/hep.24589. [Epub ahead of print]

  169. Radioembolization for hepatocellular carcinoma
    Sangro B, Iñarrairaegui M, Bilbao JI. J Hepatol. 2011 Aug 1. [Epub ahead of print]

  170. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone
    Kim HY, Park JW. Dig Dis. 2011;29(3):303-9. Epub 2011 Aug 9.

  171. Underweight patients show an increased rate of postoperative death after surgery for hepatocellular carcinoma
    Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. J Surg Oncol. 2011 Aug 3. doi: 10.1002/jso.22049. [Epub ahead of print]

  172. Level of Alpha-Fetoprotein Predicts Mortality among Patients with Hepatitis C-Related Hepatocellular Carcinoma
    Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Clin Gastroenterol Hepatol. 2011 Aug 3. [Epub ahead of print]

  173. Chronic inflammation and hepatocellular carcinoma
    Alison MR, Nicholson LJ, Lin WR. Recent Results Cancer Res. 2011;185:135-48.

  174. Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma
    Zheng S, Tansey WP, Hiebert SW, Zhao Z. BMC Med Genomics. 2011 Aug 8;4(1):62. [Epub ahead of print]

  175. Future treatment option for hepatocellular carcinoma: a focus on brivanib
    Kudo M. Dig Dis. 2011;29(3):316-20. Epub 2011 Aug 9.

  176. Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients
    Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, Miyauchi T, Arai M, Fujiwara K, Tsubota A, Takada N, Nishino T, Takashi M, Sugiura N, Kimura M, Fukai K, Yokosuka O. Oncology. 2011 Aug 3;80(5-6):366-372. [Epub ahead of print]

  177. Long term survival in patients with hepatocellular carcinoma directly invading the gastrointestinal tract: Case reports and literature review
    Lin TL, Yap AQ, Wang JH, Chen CL, Iyer SG, Low JK, Lin CC, Li WF, Chen TY, Bora D, Lin CY, Wang CC. Surg Oncol. 2011 Aug 6. [Epub ahead of print]

  178. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
    Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Hepatology. 2011 Jul 11. doi: 10.1002/hep.24551. [Epub ahead of print]

  179. Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: a meta-analysis
    Wang WM, Xu Y, Yang XR, Wang YH, Sun HX, Fan J. Hepatobiliary Pancreat Dis Int. 2011 Aug;10(4):346-55.

  180. Prospective evaluation of the management of hepatocellular carcinoma in the elderly
    Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Dig Liver Dis. 2011 Jul 26. [Epub ahead of print]

  181. Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?
    Poustchi H, Farrell G, Strasser S, Lee A, McCaughan G, George J. Hepatology. 2011 Jul 28. doi: 10.1002/hep.24581. [Epub ahead of print]

  182. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge
    Poon RT. Hepatology. 2011 Jul 25. doi: 10.1002/hep.24569. [Epub ahead of print]

  183. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma
    Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL. Dig Liver Dis. 2011 Jul 27. [Epub ahead of print]

  184. Summary of candidate selection and expanded criteria for liver transplantation for HCC: A review and consensus statement from the 2010 international consensus conference on liver transplantation for hepatocellular carcinoma
    Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon D, Freeman RB. Liver Transpl. 2011 Jul 11. doi: 10.1002/lt.22380. [Epub ahead of print]

  185. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis
    Wee A. Cytopathology. 2011 Jul 18. doi: 10.1111/j.1365-2303.2011.00882.x. [Epub ahead of print]

  186. Hepatitis C virus-related hepatocellular carcinoma and liver cirrhosis
    Pecic V, Stankovic-Djordjevic D, Nestorovic M, Radojkovic M, Marjanovic H, Ilic B, Milojkovic M. J BUON. 2011 Apr-Jun;16(2):277-81. Source Clinic for General Surgery, Clinical Center Nis, Nis, Serbia. acrepus@yahoo.com

  187. Comparison of staging systems of hepatocellular carcinoma
    Sirivatanauksorn Y, Tovikkai C. HPB Surg. 2011;2011:818217. Epub 2011 Jun 27. Sources HPB and Transplantation Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

  188. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant
    Truesdale AE, Caldwell SH, Shah NL, Argo CK, Al-Osaimi AM, Schmitt TM, Northup PG. Transpl Int. 2011 Jul 21. doi: 10.1111/j.1432-2277.2011.01299.x. [Epub ahead of print]

  189. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis
    Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Int J Cancer. 2011 Jul 21. doi: 10.1002/ijc.26301. [Epub ahead of print]

  190. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma
    Tiong L, Maddern GJ. Br J Surg. 2011 Jul 15. doi: 10.1002/bjs.7669. [Epub ahead of print]

  191. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib
    Lee JH, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Liver Int. 2011 May 3. doi: 10.1111/j.1478-3231.2011.02541.x. [Epub ahead of print]

  192. Imaging and early diagnosis of hepatocellular carcinoma
    Peck-Radosavljevic M. Minerva Gastroenterol Dietol. 2011 Sep;57(3):273-86.

  193. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience
    Semrad TJ, Gandara DR, Lara PN Jr. Ther Adv Med Oncol. 2011 Mar;3(2):95-100.

  194. M-TOR Inhibitors: What Role in Liver Transplantation?
    Kawahara T, Asthana S, Kneteman NM. J Hepatol. 2011 Jul 19. [Epub ahead of print]

  195. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC); An emerging field for advanced technologies
    Marquardt JU, Galle PR, Teufel A. J Hepatol. 2011 Jul 20. [Epub ahead of print]

  196. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration
    Teufel A, Marquardt JU, Galle PR. J Hepatol. 2011 Jul 20. [Epub ahead of print]

  197. Liver cancer and non-hodgkin lymphoma in hepatitis C virus-infected patients: results from the danvir cohort study
    Omland LH, Jepsen P, Krarup H, Christensen PB, Weis N, Nielsen L, Obel N, Sørensen HT, Stuver SO; on behalf of the DANVIR cohort study. Int J Cancer. 2011 Jul 21. doi: 10.1002/ijc.26283. [Epub ahead of print]

  198. Hepatocellular carcinoma: molecular and genomic guideline for the clinician
    Frenette C, Gish RG. Clin Liver Dis. 2011 May;15(2):307-21.

  199. Radiofrequency Ablation versus Surgical Resection as Primary Treatment of Hepatocellular Carcinoma Meeting the Milan Criteria: A Systematic Review
    Cho YK, Rhim H, Noh S. J Gastroenterol Hepatol. 2011 Jun 16. doi: 10.1111/j.1440-1746.2011.06812.x. [Epub ahead of print]

  200. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma
    Chan AC, Chok KS, Yuen WK, Chan SC, Poon RT, Lo CM, Fan ST. Arch Surg. 2011 Jun;146(6):675-81.

  201. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma
    Siddique A, Kowdley KV. Clin Liver Dis. 2011 May;15(2):281-96.

  202. Liver transplant recipient survival benefit with living donation in the MELD allocation era
    Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE. Hepatology. 2011 Jun 17. doi: 10.1002/hep.24494. [Epub ahead of print]

  203. Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma
    Saif MW, Isufi I, Peccerillo J, Syrigos KN. Gastroenterol Res Pract. 2011;2011:616080. Epub 2011 May 30.

  204. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007
    Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Viral Hepat. 2011 Jul;18(7):e232-e241. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17.

  205. The global epidemiology of hepatocellular carcinoma: present and future
    McGlynn KA, London WT. Clin Liver Dis. 2011 May;15(2):223-43.

  206. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance
    Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, Di Marco V, Farinati F, Del Poggio P, Borzio F, Borzio M, Caturelli E, Di Nolfo MA, Frigerio M, Brancaccio G, Gaeta GB. Dig Liver Dis. 2011 Jun 18. [Epub ahead of print]

  207. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study
    Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; on behalf of the Italian Liver Cancer group. Lancet Oncol. 2011 Jun 16. [Epub ahead of print]

  208. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy
    Gonzalez SA, Keeffe EB. Clin Liver Dis. 2011 May;15(2):297-306.

  209. The effect of changes of model for end-stage liver disease score during waiting time on post-liver transplant mortality
    Al-Freah MA, Gane EJ, Livingstone V, McCall J, Munn S. Hepatol Int. 2011 Jun 30. [Epub ahead of print]

  210. Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest
    Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. J Gastrointest Surg. 2011 Jul 2. [Epub ahead of print]

  211. Criteria for liver transplantation for HCC: What should the limits be?
    Silva MF, Sherman M. J Hepatol. 2011 Jun 27. [Epub ahead of print]

  212. Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study
    Kim JH, Yim HJ, Lee KG, Kim SY, Jung ES, Jung YK, Kim JH, Seo YS, Yeon JE, Lee HS, Um SH, Byun KS, Ryu HS. Hepatol Int. 2011 Jul 5. [Epub ahead of print]

  213. Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Gastroenterology. 2011 Jul 1. [Epub ahead of print]

  214. Viruses and cancers: possible role of hepatitis C virus
    Ferri C, La Civita L, Zignego AL, Pasero G. Eur J Clin Invest. 1997 Sep;27(9):711-8.

  215. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?
    Shaw JJ, Shah SA. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):365-70.

  216. Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection
    Tashiro H, Aikata H, Waki K, Amano H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Chayama K, Asahara T, Ohdan H. J Surg Oncol. 2011 Jul 1;104(1):3-9. doi: 10.1002/jso.21745.

  217. Contrast enhanced ultrasound for the characterization of hepatocellular carcinoma
    Martie A, Sporea I, Popescu A, Sirli R, D?nil? M, Serban C, Ardelean M, Bota S, Sendroiu M, Chisevescu D. Med Ultrason. 2011 Jun;13(2):108-13.

  218. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
    Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C, Molassiotis A. Eur J Oncol Nurs. 2011 Jun 2. [Epub ahead of print]

  219. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria
    Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL, Chan SC. Br J Surg. 2011 Jun 7. doi: 10.1002/bjs.7583. [Epub ahead of print]

  220. Risk Factors Influencing Postoperative Outcomes of Major Hepatic Resection of Hepatocellular Carcinoma for Patients with Underlying Liver Diseases
    Yang T, Zhang J, Lu JH, Yang GS, Wu MC, Yu WF. World J Surg. 2011 Jun 9. [Epub ahead of print]

  221. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction
    Hsin IF, Hsu CY, Huang HC, Huang YH, Lin HC, Lee RC, Chiang JH, Lee FY, Huo TI, Lee SD. J Clin Gastroenterol. 2011 Jul;45(6):556-62.

  222. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
    Williet N, Dubreuil O, Boussaha T, Trouilloud I, Landi B, Housset M, Botti M, Rougier P, Belghiti J, Taieb J. World J Gastroenterol. 2011 May 7;17(17):2255-8.

  223. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
    Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Eur J Cancer. 2011 Jun 9. [Epub ahead of print]

  224. Current concepts in transarterial chemoembolization of hepatocellular carcinoma
    Huppert P. Abdom Imaging. 2011 Jun 15. [Epub ahead of print]

  225. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis
    Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Gastrointest Cancer Res. 2011 Mar;4(2):40-4.

  226. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection
    Hsu A, Lai CL, Yuen MF. Curr Hepat Rep. 2011 Jun;10(2):106-111. Epub 2011 Feb 19.

  227. Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation
    Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; on behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Hepatology. 2011 May 26. doi: 10.1002/hep.24451. [Epub ahead of print]

  228. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers
    Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, Cucchetti A, D'errico-Grigioni A, Golfieri R, Pinna AD. Transplantation. 2011 Jun 15;91(11):1279-85.

  229. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C
    Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. J Gastroenterol Hepatol. 2011 May 26. doi: 10.1111/j.1440-1746.2011.06785.x. [Epub ahead of print]

  230. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients
    Ataide EC, Boin IF, Almeida JR, Sevá-Pereira T, Stucchi RS, Cardoso AR, Caruy CA, Escanhoela CA. Transplant Proc. 2011 May;43(4):1362-4.

  231. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
    Vernon G, Baranova A, Younossi ZM. Aliment Pharmacol Ther. 2011 May 30. doi: 10.1111/j.1365-2036.2011.04724.x. [Epub ahead of print]

  232. The impact of milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the hungarian liver transplant program
    Nemes B, Gelley F, Piros L, Zádori G, Görög D, Fehérvári I, Kóbori L, Sárváry E, Nagy P, Kiss A, Doros A. Transplant Proc. 2011 May;43(4):1272-4.

  233. T oSystematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria
    Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Br J Surg. 2011 May 27. doi: 10.1002/bjs.7561. [Epub ahead of print]

  234. Sorafenib enhances pemetrexed cytotoxicity through an autophagy -dependent mechanism in cancer cells
    Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Cancer Res. 2011 May 27. [Epub ahead of print]

  235. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension
    Elia C, Venon WD, Stradella D, Martini S, Brunello F, Marzano A, Saracco G, Rizzetto M. Eur J Gastroenterol Hepatol. 2011 May 4. [Epub ahead of print]

  236. Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation
    Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Yu YD, Park PJ, Choi YI, Kim KW, Lim YS, Lee HC, Yu ES, Lee SG. J Gastrointest Surg. 2011 Jun;15(6):971-81. Epub 2011 Mar 29.

  237. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma
    Tsai YJ, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee SD. Hepatol Int. 2011 Apr 30. [Epub ahead of print]

  238. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index
    Kao WY, Chiou YY, Hung HH, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lin HC, Lee SD. Eur J Gastroenterol Hepatol. 2011 Jun;23(6):528-36.

  239. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta-analysis of cohort studies
    Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L. Int J Cancer. 2011 May 4. doi: 10.1002/ijc.26165. [Epub ahead of print]

  240. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention
    Giacomin A, Cazzagon N, Sergio A, Vanin V, Farinati F. Eur J Cancer Prev. 2011 May 2. [Epub ahead of print]

  241. Metabolic syndrome increases the risk of primary liver cancer in the United States: A population-based case-control study.
    Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Hepatology. 2011 Apr 29. doi: 10.1002/hep.24397. [Epub ahead of print]

  242. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up
    Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z. World J Gastroenterol. 2011 Apr 28;17(16):2143-9.

  243. Safety of hepatic resection in overweight and obese patients with cirrhosis
    Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Br J Surg. 2011 Apr 20. doi: 10.1002/bjs.7516. [Epub ahead of print]

  244. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination
    Kim KA, Kim MJ, Choi JY, Chung YE. Eur J Radiol. 2011 Apr 21. [Epub ahead of print]

  245. Surgical Outcomes for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
    Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K.SourceJ Gastrointest Surg. 2011 Apr 22. [Epub ahead of print]

  246. Fibrosis in chronic viral hepatitis
    Calvaruso V, Craxì A. Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):219-30.

  247. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis
    Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, Chiang JH, Huo TI, Lee FY, Lee SD. Liver Transpl. 2011 May;17(5):556-66. doi: 10.1002/lt.22273.

  248. Immunosuppression and hepatocellular carcinoma
    Hj S, F M, A S, Jf T. Liver Transpl. 2011 Apr 19. doi: 10.1002/lt.22318. [Epub ahead of print]

  249. Hepatocellular carcinoma and liver transplantation
    Washburn K, Halff G. Curr Opin Organ Transplant. 2011 Apr 17. [Epub ahead of print]

  250. Effect of Oral Supplementation with Branched-chain Amino Acid (BCAA) during Radiotherapy in Patients with Hepatocellular Carcinoma: A Double-Blind Randomized Study
    Lee IJ, Seong J, Bae JI, You SH, Rhee Y, Lee JH. Cancer Res Treat. 2011 Mar;43(1):24-31. Epub 2011 Mar 31. Cancer Res Treat. 2011 Mar;43(1):24-31. Epub 2011 Mar 31

  251. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma
    Chua TC, Morris DL. Surg Oncol. 2011 Mar 10. [Epub ahead of print]

  252. Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era
    Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. World J Surg. 2011 May;35(5):1072-84.

  253. Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation
    Yun WK, Choi MS, Choi D, Rhim HC, Joh JW, Kim KH, Jang TH, Lee JH, Koh KC, Paik SW, Yoo BC. Hepatol Int. 2010 Dec 25. [Epub ahead of print]

  254. Transarterial chemoembolization as salvage therapy after unsuccessful hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma
    Fukumori K, Yano Y, Ando E, Sumie S, Kuwaki K, Yamashita F, Tanaka M, Sata M. Mol Med Report. 2008 Jul-Aug;1(4):521-4.

  255. FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria
    Sun H, Teng M, Liu J, Jin D, Wu J, Yan D, Fan J, Qin X, Tang H, Peng Z. Cancer Lett. 2011 Apr 9. [Epub ahead of print]

  256. Cancer risk in chronic hepatitis B: Do genome-wide association studies hit the mark?
    Casper M, Grünhage F, Lammert F. Hepatology. 2011 Apr;53(4):1390-2. doi: 10.1002/hep.24241.

  257. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma
    Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Tsuge M, Chayama K. Hepatology. 2011 Apr;53(4):1237-45. doi: 10.1002/hep.24207.

  258. Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B
    Long J, Wang H, Lang Z, Wang T, Long M, Wang B. Hepatol Int. 2010 Dec 28. [Epub ahead of print]

  259. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
    Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, Toriyabe T, Shinozaki Y, Ooka Y, Mikata R, Chiba T, Okabe S, Imazeki F, Yoshikawa M, Yokosuka O. Hepatol Int. 2011 Jan 22. [Epub ahead of print]

  260. Assessment of hepatocellular carcinomas using conventional magnetic resonance imaging correlated with histological differentiation and a serum marker of poor prognosis
    Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Hepatol Int. 2011 Jan 9. [Epub ahead of print]

  261. Treatment options in hepatocellular carcinoma today
    Livraghi T, Mäkisalo H, Line PD. Scand J Surg. 2011;100(1):22-9.

  262. Therapeutic options for intermediate-advanced hepatocellular carcinoma
    Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. World J Gastroenterol. 2011 Apr 7;17(13):1685-9.

  263. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation
    Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, Koike K, Omata M. Hepatol Int. 2011 Jan 25. [Epub ahead of print]

  264. MR-arterioportography: A new technical approach for detection of liver lesions
    Rennert J, Jung EM, Schreyer AG, Hoffstetter P, Heiss P, Feuerbach S, Zorger N. World J Gastroenterol. 2011 Apr 7;17(13):1739-45.

  265. Gene profiling of early and advanced liver disease in chronic hepatitis C patients
    Khalid SS, Hamid S, Siddiqui AA, Qureshi A, Qureshi N. Hepatol Int. 2011 Jan 22. [Epub ahead of print]

  266. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience
    Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Ann Surg. 2011 Apr;253(4):745-58.

  267. Prognosis of patients with hepatocellular carcinoma after hepatic resection: Are elderly patients suitable for surgery?
    Nanashima A, Abo T, Nonaka T, Fukuoka H, Hidaka S, Takeshita H, Ichikawa T, Sawai T, Yasutake T, Nakao K, Nagayasu T. J Surg Oncol. 2011 Apr 1. doi: 10.1002/jso.21932. [Epub ahead of print]

  268. A Functional Polymorphism in the Epidermal Growth Factor Gene is Associated with Risk for Hepatocellular Carcinoma
    Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group. Gastroenterology. 2011 Mar 24. [Epub ahead of print]

  269. Progression of liver cirrhosis to HCC: an application of hidden Markov model
    Bartolomeo N, Trerotoli P, Serio G. BMC Med Res Methodol. 2011 Apr 4;11(1):38. [Epub ahead of print]

  270. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection
    Yamashita T, Honda M, Kaneko S. J Gastroenterol Hepatol. 2011 Mar 28. doi: 10.1111/j.1440-1746.2011.06723.x. [Epub ahead of print]

  271. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Cancer Chemother Pharmacol. 2011 Mar 29. [Epub ahead of print]

  272. Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs in the United States
    Bini Deceased EJ, Kritz S, Brown LS Jr, Robinson J, Alderson D, Rotrosen J. J Addict Dis. 2011 Apr;30(2):98-109.

  273. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C
    Sato S, Genda T, Hirano K, Tsuzura H, Kanemitsu Y, Narita Y, Kikuchi T, Ijima K, Ichida T. Hepatol Int. 2011 Apr 2. [Epub ahead of print]

  274. Racial differences in hepatitis C treatment eligibility
    Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; on behalf of the IDEAL Study Team. Hepatology. 2011 Apr 12. doi: 10.1002/hep.24358. [Epub ahead of print]

  275. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma
    Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. AJR Am J Roentgenol. 2011 Apr;196(4):919-28.

  276. Surveillance of small intestinal abnormalities in patients with hepatocellular carcinoma: a prospective capsule endoscopy study
    Yamada A, Watabe H, Obi S, Sugimoto T, Kondo S, Ohta M, Togo G, Ogura K, Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Koike K, Omata M. Dig Endosc. 2011 Apr;23(2):124-9. doi: 10.1111/j.1443-1661.2010.01050.x. Epub 2010 Dec 7.

  277. Strategies for HCC therapy and diagnostics - lessons learned from high throughput and profiling approaches
    Breuhahn K, Gores G, Schirmacher P. Hepatology. 2011 Mar 23. doi: 10.1002/hep.24313. [Epub ahead of print]

  278. Radiofrequency ablation for hepatocellular carcinoma: use of low versus maximal radiofrequency power
    Macatula TC, Lin CC, Lin CJ, Chen WT, Lin SM. Br J Radiol. 2011 Mar 22. [Epub ahead of print]

  279. Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: comparison of effects of thermal protection and therapeutic efficacy
    Kang TW, Rhim H, Lee MW, Kim YS, Choi D, Lee WJ, Lim HK. AJR Am J Roentgenol. 2011 Apr;196(4):907-13.

  280. Molecular predictors of response to antiangiogenesis therapies
    Gerger A, Labonte M, Lenz HJ. Cancer J. 2011 Mar-Apr;17(2):134-41.

  281. Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
    Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH. Mol Ther. 2011 Mar 22. [Epub ahead of print]

  282. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Cancer Chemother Pharmacol. 2011 Mar 29. [Epub ahead of print]

  283. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection
    Yamashita T, Honda M, Kaneko S. J Gastroenterol Hepatol. 2011 Mar 28. doi: 10.1111/j.1440-1746.2011.06723.x. [Epub ahead of print]

  284. Progression of liver cirrhosis to HCC: an application of hidden Markov model
    Bartolomeo N, Trerotoli P, Serio G. BMC Med Res Methodol. 2011 Apr 4;11(1):38. [Epub ahead of print]

  285. Sorafenib-induced premalignant and malignant skin lesions
    Williams VL, Cohen PR, Stewart DJ. Int J Dermatol. 2011 Apr;50(4):396-402. doi: 10.1111/j.1365-4632.2010.04822.x.

  286. Radiofrequency ablation of hepatocellular carcinoma
    Livraghi T. Surg Oncol Clin N Am. 2011 Apr;20(2):281-99.

  287. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management
    Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Radiology. 2011 Mar;258(3):673-93

  288. Sorafenib-associated hand-foot syndrome in Japanese patients
    Iijima M, Fukino K, Adachi M, Tsukamoto T, Murai M, Naito S, Minami H, Furuse J, Akaza H. J Dermatol. 2011 Mar;38(3):261-266

  289. Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma
    Kaibori M, Ishizaki M, Matsui K, Kitade H, Matsui Y, Kwon AH. J Gastroenterol Hepatol. 2011 Mar;26(3):536-43.

  290. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy
    Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. J Gastroenterol. 2011 Mar 4. [Epub ahead of print]

  291. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in us patients with chronic hepatitis C
    Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; the HALT-C Trial Group. Hepatology. 2011 Mar 3. [Epub ahead of print]

  292. Computed Tomography Findings of Sorafenib-treated Hepatic Tumors in Patients with Advanced Hepatocellular Carcinoma
    Kim MJ, Choi JI, Lee JS, Park JW. J Gastroenterol Hepatol. 2011 Mar 3. [Epub ahead of print]

  293. Repeated liver resection for recurrent hepatocellular carcinoma
    Faber W, Seehofer D, Neuhaus P, Stockmann M, Denecke T, Kalmuk S, Warnick P, Bahra M. J Gastroenterol Hepatol. 2011 Mar 16. doi: 10.1111/j.1440-1746.2011.06721.x. [Epub ahead of print]

  294. Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors
    Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Br J Clin Pharmacol. 2011 Mar 11. doi: 10.1111/j.1365-2125.2011.03963.x. [Epub ahead of print]

  295. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
    Oliveri RS, Wetterslev J, Gluud C. Cochrane Database Syst Rev. 2011 Mar 16;3:CD004787.

  296. Hepatocellular Carcinoma: Prevention and Therapy
    Sohal DP, Sun W. Curr Oncol Rep. 2011 Mar 17. [Epub ahead of print]

  297. Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer
    Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M. Med Oncol. 2011 Mar 17. [Epub ahead of print]

  298. The Management of Hospitalized Patients with Cirrhosis: The Mount Sinai Experience and a Guide for Hospitalists
    Perumalswami PV, Schiano TD. Dig Dis Sci. 2011 Mar 18. [Epub ahead of print]

  299. Targeted Therapies for Hepatocellular Carcinoma
    Villanueva A, Llovet JM. Gastroenterology. 2011 Mar 12. [Epub ahead of print]

  300. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients
    Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. World J Gastroenterol. 2011 Feb 21;17(7):914-21.

  301. Sorafenib for advanced hepatocellular carcinoma: a systematic review
    Ling Lin Z, Li M, Jin-Hui T, Ke Hu Y. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Feb 10;33(1):51-7.

  302. Hepatic Resection for Transplantable Hepatocellular Carcinoma for Patients Within Milan and UCSF Criteria
    Chua TC, Saxena A, Chu F, Morris DL. Am J Clin Oncol. 2011 Feb 17. [Epub ahead of print]

  303. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
    Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group, The Ministry of Health, Labour and Welfare of Japan. Clin Gastroenterol Hepatol. 2011 Feb 11. [Epub ahead of print]

  304. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
    Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TT. J Hepatol. 2011 Feb 18. [Epub ahead of print]

  305. Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience
    Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, Lam CM, Ng KK, Chan SC. Ann Surg. 2011 Feb 17. [Epub ahead of print]

  306. A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma
    Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. Oncologist. 2011 Feb 24. [Epub

  307. Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma
    Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas MB, Harris R, Baudelet C, Walters I, Raoul J. Clin Cancer Res. 2011 Feb 24. [Epub ahead of print]

  308. Prognostic Factors and 10-Year Survival in Patients with Hepatocellular Carcinoma After Curative Hepatectomy
    Kim SH, Choi SB, Lee JG, Kim SU, Park MS, Kim DY, Choi JS, Kim KS. J Gastrointest Surg. 2011 Feb 19. [Epub ahead of print]

  309. Efficacy of selective transarterial chemoembolization in obtaining tumor necrosis in small (<5 cm) hepatocellular carcinomas
    Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, Ravaioli M, D'Errico-Grigioni A, Pinna AD, Bolondi L. Hepatology. 2011 Feb 23.[Epub ahead of print]

  310. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies
    Tanaka S, Arii S. J Gastroenterol. 2011 Feb 25. [Epub ahead of print]

  311. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib
    Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, Sogni P, Pol S, Blanchet B, Legmann P, Goldwasser F. PLoS One. 2011 Feb 14

  312. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways
    Schattenberg JM, Schuchmann M, Galle PR. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:213-9.

  313. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies
    Lord R, Suddle A, Ross PJ. Int J Clin Pract. 2011 Feb;65(2):182-8.

  314. Building a Comprehensive Genomic Program for Hepatocellular Carcinoma
    Harring TR, Guiteau JJ, Nguyen NT, Cotton RT, Gingras MC, Wheeler DA, O'Mahony CA, Gibbs RA, Brunicardi FC, Goss JA. World J Surg. 2011 Jan 12. [Epub ahead of print]

  315. A clustered ground-glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery
    Tsai HW, Lin YJ, Lin PW, Wu HC, Hsu KH, Yen CJ, Chan SH, Huang W, Su IJ. Cancer. 2011 Jan 10. [Epub ahead of print]

  316. Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B
    Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. J Infect Dis. 2011 Jan 12. [Epub ahead of print]

  317. Comparison of Differences and Determinants Between Presence and Absence of Sleep Disturbance in Hepatocellular Carcinoma Patients
    Chu TL, Yu WP, Chen SC, Peng HL, Wu MJ. Cancer Nurs. 2011 Jan 15. [Epub ahead of print]

  318. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States
    Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Ann Intern Med. 2011 Jan 18;154(2):85-93.

  319. Sorafenib and radiotherapy association for hepatocellular carcinoma
    Girard N, Mornex F. Cancer Radiother. 2011 Jan 14. [Epub ahead of print]

  320. Evaluation of Absolute Serum {alpha}-Fetoprotein Levels in Liver Transplant for Hepatocellular Cancer
    Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, Bhatia S, Nissen N, Colquhoun SD, Kim J. Arch Surg. 2011 Jan;146(1):26-33.

  321. Assessment of Chronic Hepatitis B - the importance of HBV DNA testing
    Croagh CM, Bell SJ, Locarnini S, Desmond PV. Intern Med J. 2011 Jan 17. [Epub ahead of print]

  322. Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome?
    Belghiti J, Durand F. Liver Int. 2011 Jan;31 Suppl 1:161-3

  323. Clinical Significance of Alpha-Fetoprotein mRNA in Peripheral Blood in Liver Resection for Hepatocellular Carcinoma
    Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Ann Surg Oncol. 2011 Feb 8. [Epub ahead of print]

  324. Hepatocellular Carcinoma in Older Adults: Clinical Features, Treatments, and Survival
    Lee SH, Choi HC, Jeong SH, Lee KH, Chung JI, Park YS, Hwang JH, Kim JW, Kim N, Lee DH, Choi HC, Yoon CJ, Kang SG. J Am Geriatr Soc. 2011 Jan 28. [Epub ahead of print]

  325. Advanced hepatocellular carcinoma. Review of targeted molecular drugs
    Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P. Ann Hepatol. 2011 Jan 3;10(1):21-7.

  326. Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis
    Schütte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, Malfertheiner P. Digestion. 2011 Feb 1;83(4):275-282. [Epub ahead of print]

  327. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population
    Li Y, Chang SC, Goldstein BY, Scheider WL, Cai L, You NC, Tarleton HP, Ding B, Zhao J, Wu M, Jiang Q, Yu S, Rao J, Lu QY, Zhang ZF, Mu L. Cancer Epidemiol. 2011 Feb 9. [Epub ahead of print]

  328. Hepatocellular cancer in the non-cirrhotic liver
    Alkofer B, Lepennec V, Chiche L. J Visc Surg. 2011 Feb 7. [Epub ahead of print]

  329. Molecular Pathogenesis of Hepatocellular Carcinoma
    Cornellà H, Alsinet C, Villanueva A. Alcohol Clin Exp Res. 2011 Feb 8. [Epub ahead of print]

  330. Hepatitis B Virus Core Protein Variations Differ in Tumor and Adjacent Nontumor Tissues from Patients with Hepatocellular Carcinoma
    Zhu Y, Jin Y, Cai X, Bai X, Chen M, Chen T, Wang J, Qian G, Gu J, Li J, Tu H. Intervirology. 2011 Feb 16. [Epub ahead of print]

  331. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma
    Guan YS, He Q. Expert Opin Pharmacother. 2011 Feb;12(2):303-13.

  332. HBV-related HCC, clinical issues and therapy
    Iavarone M, Colombo M. Dig Liver Dis. 2011 Jan;43 Suppl 1:S32-9

  333. Recent advances of radiofrequency ablation for early hepatocellular carcinoma
    Izumi N. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:115-22.

  334. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?
    Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, Yoon HK, Sung KB, Lee JL, Kang YK, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. J Gastroenterol Hepatol. 2011 Jan;26(1):145-54..

  335. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience
    Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A. Transplant Proc. 2010 Dec;42(10):4582-4.

  336. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Saab S, McTigue M, Finn RS, Busuttil RW. Exp Clin Transplant. 2010 Dec;8(4):307-13.

  337. PI-103 and Sorafenib Inhibit Hepatocellular Carcinoma Cell Proliferation by Blocking Ras/Raf/MAPK and PI3K/AKT/mTOR Pathways
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. Anticancer Res. 2010 Dec;30(12):4951-8.

  338. Established and emerging therapies for hepatocellular carcinoma
    Cicinnati VR, Sotiropoulos GC, Beckebaum S. Minerva Med. 2010 Dec;101(6):405-18.

  339. A Comparison of Prognosis between Patients with Hepatitis B and C Virus-related Hepatocellular Carcinoma Undergoing Resection Surgery
    Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. World J Surg. 2011 Jan 5. [Epub ahead of print]

  340. Understanding Surgical Decision Making in Early Hepatocellular Carcinoma
    Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, Wolfgang CL, Segev DL, Choti MA, Pawlik TM. J Clin Oncol. 2011 Jan 4. [Epub ahead of print]

  341. Hepatocellular carcinoma: the place of new medical therapies
    Peck-Radosavljevic M. Therap Adv Gastroenterol. 2010 Jul;3(4):259-67.

  342. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma
    Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Korean J Hepatol. 2010 Dec;16():383-8.

  343. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma
    Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Int J Clin Oncol. 2010 Dec 9. [Epub ahead of print]

  344. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm
    Sulkes A. Isr Med Assoc J. 2010 Oct;12(10):628-32.

  345. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation
    Dubay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD. HPB (Oxford). 2011 Jan;13(1):24-32. Epub 2010 Nov 8.

  346. Sorafenib Modulates the Gene Expression of Multi-drug Resistance Mediating ATP-Binding Cassette Proteins in Experimental Hepatocellular Carcinoma
    Hoffmann K, Franz C, Xiao Z, Mohr E, Serba S, Büchler MW, Schemmer P. Anticancer Res. 2010 Nov;30(11):4503-8

  347. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation
    Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH, Yan PN, Zhang BH, Wu MC, Luo XJ, Jiang XQ. Acta Pharmacol Sin. 2010 Dec;31(12):1643-8. Epub 2010 Nov 22.

  348. Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
    Xu LT, Chen Z, Lin JH, Zhou ZH, Chen H, Meng ZQ, Liu LM. Zhonghua Zhong Liu Za Zhi. 2010 Sep;32(9):703-705.

  349. Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma
    Zhang L, Ren ZG, Gan YH, Wang YH, Zhang BH, Chen Y, Xie XY, Ge NL, Ye SL. Zhonghua Zhong Liu Za Zhi. 2010 Aug;32(8):630-3.

  350. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program
    Chen WT, Fernandes ML, Lin CC, Lin SM. J Surg Oncol. 2010 Dec 7. [Epub ahead of print]

  351. Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor
    Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, Sironi S. World J Gastroenterol. 2010 Dec 21;16(47):5993-6000.

  352. Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib
    Spira D, Fenchel M, Lauer UM, Claussen CD, Gregor M, Bitzer M, Horger M. Acad Radiol. 2010 Oct 5. [Epub ahead of print]

  353. Clinical Management and Case Reports for the Treatment of Hepatocellular Carcinoma With Sorafenib
    Frenette CT, Frederick RT, Gish RG. J Clin Gastroenterol. 2010 Oct 6. [Epub ahead of print]

  354. Treatment of hepatitis C infections with interferon: a historical perspective
    Friedman RM, Contente S. Hepat Res Treat. 2010.Epub 2010 Sep 6.

  355. Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans
    Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2010 Oct 2. [Epub ahead of print]

  356. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
    Scartozzi M, Svegliati Baroni G, Faloppi L, Di Pietro Paolo M, Pierantoni C, Candelari R, Berardi R, Antognoli S, Mincarelli C, Risaliti A, Marmorale C, Antico E, Benedetti A, Cascinu S. J Exp Clin Cancer Res. 2010 Dec 15;29(1):164. [Epub ahead of print]

  357. Hepatocellular carcinoma in thalassemia: A critical review
    Mancuso A. World J Hepatol. 2010 May 27;2(5):171-4.

  358. Liver Cancer Working Group report
    Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i19-27.

  359. Latest developments in targeted therapy for hepatocellular carcinoma
    Montella L, Addeo R, Caraglia M, Del Prete S. Expert Rev Anticancer Ther. 2010 Oct;10(10):1635-46.

  360. Underutilization of therapy for hepatocellular carcinoma in the medicare population
    Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Cancer. 2010 Oct 13. [Epub ahead of print]

  361. Developing better treatments in hepatocellular carcinoma
    Duffy A, Greten T. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):551-60.

  362. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy
    Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Hepatol Res. 2010 Sep;40(9):870-7.

  363. Comparative Analysis of Outcome in Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria Treated With Liver Transplantation Versus Partial Hepatectomy
    Canter RJ, Patel SA, Kennedy T, D?angelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, Dematteo RP, Abt PL. Am J Clin Oncol. 2010 Oct 8. [Epub ahead of print]

  364. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. Am J Med. 2010 Oct;123(10):951-956.e1.

  365. Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data
    Richardson P, Henderson L, Davila JA, Kramer JR, Fitton CP, Chen GJ, El-Serag HB. Dig Dis Sci. 2010 Sep 16. [Epub ahead of print]

  366. Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results
    Peng ZW, Zhang YJ, Chen MS, Lin XJ, Liang HH, Shi M. Eur J Surg Oncol. 2010 Sep 14. [Epub ahead of print]

  367. Sorafenib in hepatocellular carcinoma
    Josephs DH, Ross PJ. Br J Hosp Med (Lond). 2010 Aug;71(8):451-6.

  368. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma
    Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. World J Gastroenterol. 2010 Sep 21;16(35):4410-5.

  369. Effects of Pegylated Interferon α2b on Metastasis of Hepatocellular Carcinoma
    Arakawa Y, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T. J Surg Res. 2010 Aug 6. [Epub ahead of print]

  370. Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study
    Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ. J Clin Oncol. 2010 Sep 20. [Epub ahead of print]

  371. Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation
    Iavarone M, Sangiovanni A, Forzenigo LV, Massironi S, Fraquelli M, Aghemo A, Ronchi G, Biondetti P, Roncalli M, Colombo M. Hepatology. 2010 Aug 19. [Epub ahead of print]

  372. High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients.
    Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB, Xia JC. World J Gastroenterol. 2010 Sep 28;16(36):4611-4615.

  373. Hepatitis B Genotype C Correlated with Poor Surgical Outcomes for Hepatocellular Carcinoma
    Liang TJ, Mok KT, Liu SI, Huang SF, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC, Wang BW. J Am Coll Surg. 2010 Sep 17. [Epub ahead of print]

  374. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigms
    Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P. Pathol Biol (Paris). 2010 Jul 26. [Epub ahead of print]

  375. Identification of Novel Methylation Markers in Hepatocellular Carcinoma using a Methylation Array
    Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. J Korean Med Sci. 2010 Aug;25(8):1152-9. Epub 2010 Jul 20.

  376. Macrophage migration inhibitory factor plays a pivotal role in hepatocellular carcinoma and may be a noninvasive imaging target
    Han Y, Zhang C. Med Hypotheses. 2010 Jul 31. [Epub ahead of print]

  377. Non-viral causes of hepatocellular carcinoma
    Blonski W, Kotlyar DS, Forde KA. World J Gastroenterol. 2010 Aug 7;16(29):3603-15.

  378. Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study
    Hull D, Armstrong C. Int J Palliat Nurs. 2010 May;16(5):249-54.

  379. Pathology of hepatocellular carcinoma
    Mori W, Machinami R, Tanaka K. Pathol Res Pract. 1980;169(1):4-20.

  380. Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting
    Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. J Clin Oncol. 2010 Aug 2. [Epub ahead of print]

  381. AASLD PRACTICE GUIDELINE: Management of Hepatocellular Carcinoma: An Update
    Bruix J and Sherman M. Hepatology July 2010;000 (000:;1-35)

  382. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy
    Kudo M. J Gastroenterol Hepatol. 2010 Mar;25(3):439-52.

  383. Antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma: an open randomized prospective study of oral versus intravenous administration
    Ebisutani C, Sato S, Nishi K, Inoue H, Yoshie T, Kinoshita Y. Intern Med. 2010;49(12):1059-65. Epub 2010 Jun 15.

  384. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems
    Zhang XF, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Eur J Surg Oncol. 2010 Jun 8. [Epub ahead of print]

  385. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma
    Zhu AX. Expert Opin Investig Drugs. 2010 May;19(5):663-72.

  386. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort
    Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Radiology. 2010 Jun;255(3):955-65.

  387. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience
    Perrella A, Esposito C, Ioia G, Campanella L, Taglialatela D, Cuomo O. Transplant Proc. 2010 May;42(4):1226-8.

  388. High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue Is Associated with Poor Outcome in Hepatocellular Carcinoma After Curative Resection
    Jia JB, Wang WQ, Sun HC, Zhu XD, Liu L, Zhuang PY, Zhang JB, Zhang W, Xu HX, Kong LQ, Lu L, Wu WZ, Wang L, Tang ZY. Oncologist. 2010 Jun 15. [Epub ahead of print]

  389. Epidemiology, risk factors and surveillance of hepatocellular carcinoma
    Cabibbo G, Craxì A. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):352-5.

  390. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis
    Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH. Histopathology. 2010 May;56(6):683-93.

  391. Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old
    Colak D, Chishti MA, Al-Bakheet AB, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH, Kaya N. Mol Cancer. 2010 Jun 12;9(1):146. [Epub ahead of print]

  392. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy
    Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM. J Clin Pathol. 2010 May 24. [Epub ahead of print]

  393. Hepatocellular carcinoma in unrelated viral cirrhosis: long-term results after liver transplantation
    Lauterio A, Di Sandro S, Slim A, Giacomoni A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, De Carlis L. Transplant Proc. 2010 May;42(4):1212-5.

  394. Expression profile reveals novel prognostic biomarkers in hepatocellular carcinoma
    Sun M, Wu G, Li Y, Fu X, Huang Y, Tang R, Guo Y, Qiu M, Mao Y, Zhao F, Li L, Huang S, Zhao X, Xie Y. Front Biosci (Elite Ed). 2010 Jun 1;2:829-40.

  395. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
    Hessheimer AJ, Forner A, Varela M, Bruix J. Eur J Gastroenterol Hepatol. 2010 May 25. [Epub ahead of print]

  396. Molecularly targeted therapy in hepatocellular carcinoma
    Huynh H. Biochem Pharmacol. 2010 Apr 4. [Epub ahead of print]

  397. Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol. 2010 Jun;15(3):235-41
    Tanaka S, Arii S. Epub 2010 May 27

  398. Novel inhibitors in development for hepatocellular carcinoma
    Wörns MA, Galle PR. Expert Opin Investig Drugs. 2010 May;19(5):615-29.

  399. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis
    Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. World J Gastroenterol. 2010 Jun 21;16(23):2931-42.

  400. Prognostic Impact of Underlying Liver Fibrosis and Cirrhosis After Curative Resection of Hepatocellular Carcinoma
    Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. World J Surg. 2010 Jun 11. [Epub ahead of print]

  401. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection
    Wang DD, Zhao YM, Wang L, Ren G, Wang F, Xia ZG, Wang XL, Zhang T, Pan Q, Dai Z, Chen JP, Dai HY, Zhang W, He HW, Zhou JM, Tang GY, Zhou J, Fan J, Tang ZY. J Cancer Res Clin Oncol. 2010 Jun 15. [Epub ahead of print]

  402. Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease
    Shoji B, Ikeda F, Fujioka SI, Kobashi H, Yasunaka T, Miyake Y, Shiraha H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. J Gastroenterol. 2010 Jun 12. [Epub ahead of print]

  403. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma
    Kuroda H, Kasai K, Kakisaka K, Yasumi Y, Kataoka K, Ushio A, Miyamoto Y, Sawara K, Oikawa K, Kondo K, Miura Y, Endo R, Takikawa Y, Suzuki K. Hepatol Res. 2010 May;40(5):550-4.

  404. Laparoscopic ultrasound-guided radiofrequency ablation as a bridge to liver transplantation for hepatocellular carcinoma: preliminary results
    Panaro F, Piardi T, Audet M, Gheza F, Woehl-Jaegle ML, Portolani N, Cinqualbre J, Wolf P. Transplant Proc. 2010 May;42(4):1179-81.

  405. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital
    Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P. J Gastroenterol Hepatol. 2010 May;25(5):951-6.

  406. Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma
    Welker MW, Zangos S, Kriener S, Mönch C, Zeuzem S, Trojan J. J Gastrointest Cancer. 2010 Jun;41(2):149-52.

  407. Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population
    Park MJ, Kim YS, Lee WJ, Lim HK, Rhim H, Lee J. Eur Radiol. 2010 Jun 19. [Epub ahead of print]

  408. Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation
    Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK. Jpn J Clin Oncol. 2010 May 21. [Epub ahead of print]

  409. A Single-Institute Experience with Sorafenib in Untreated and Previously Treated Patients with Advanced Hepatocellular Carcinoma
    Balsom SM, Li X, Trolli E, Rose J, Bloomston M, Patel T, Bekaii-Saab TS. Oncology. 2010 Apr 26;78(3-4):210-212. [Epub ahead of print]

  410. Sorafenib for the treatment of advanced hepatocellular carcinoma
    Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Health Technol Assess. 2010 May;14 Suppl 1:17-21.

  411. Hepatocellular carcinoma: occurrence, risk factors, biomarkers
    Fehér J, Lengyel G. Orv Hetil. 2010 Jun 6;151(23):933-40

  412. Downstaging of Hepatocellular Carcinoma Prior to Liver Transplant: Is There a Role for Adjuvant Sorafenib in Locoregional Therapy?
    Vagefi PA, Hirose R. J Gastrointest Cancer. 2010 May 5. [Epub ahead of print]

  413. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future
    Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Cancer Control. 2010 Apr;17(1):120-9.

  414. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX. Ann Surg Oncol. 2010 May;17(5):1247-56. Epub 2010 Apr 20.

  415. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
    Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, Gasbarrini G, Landolfi R, Grieco A. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):356-62.

  416. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice
    Kudo M. Int J Clin Oncol. 2010 Jun;15(3):242-55. Epub 2010 May 28.

  417. Targeted therapies in hepatocellular carcinoma
    Bouattour M, Marijon H, Dreyer C, Faivre S, Raymond E. Presse Med. 2010 Apr 6. [Epub ahead of print]

  418. Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria
    Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D, Madariaga J, Dervenis C. HPB (Oxford). 2009 Nov;11(7):551-8.

  419. Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation
    Vitale A, Volk ML, Gambato M, Zanus G, D'Amico F, Carraro A, Pauletto A, Bonsignore P, Scopelliti M, Polacco M, Russo F, Senzolo M, Burra P, Romano A, Angeli P, Cillo U. Transplant Proc. 2010 May;42(4):1194-6

  420. Subtype classification of hepatocellular adenoma
    Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Dig Surg. 2010;27(1):39-45.
    Epub 2010 Apr 1.

  421. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis
    Cardoso A, Moucan R, Figueiredo-Mendes et al.J Hep 2010 (Mar 3).

  422. Treatment of advanced hepatocellular carcinoma
    Forner A, Rodríguez De Lope C, Reig M, Bruix J. Gastroenterol Hepatol. 2010 Mar 12. [Epub ahead of print]

  423. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
    Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F. Eur J Gastroenterol Hepatol 2010 Mar 17

  424. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma
    Peck-Radosavljevic M, Greten TF, Lammer, J, Rosmorduc O, Sangro,B, Santoro A, Bolondi L. Eur J Gastroenterol Hepatol April 2010;22:391-398.

  425. Survival in Asian Americans After Treatments for Hepatocellular Carcinoma: A Seven-year Experience at UCLA
    Tong M, Chavalitdhamrong D, Lu D, Raman S, Gomes A, Duffy J, Hong J, Busuttil R. J Clin Gastroenterol 2010;44(3):e63-e70.

  426. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
    Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. Hepatology. 2009 Dec 4. [Epub ahead of print]

  427. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis
    Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. J Hepatol. 2010 Jan 17. [Epub ahead of print]

  428. Sorafenib in advanced hepatocellular carcinoma
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. N Engl J Med. 2008 Jul 24;359(4):378-90

  429. Design and endpoints of clinical tria ls in hepatocellular carcinoma
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. J Natl Cancer Inst. 2008 May 21;100(10):698-711. Epub 2008 May 13

  430. Molecular targeted therapies in hepatocellular carcinoma
    Llovet JM, Bruix J. Hepatology. 2008 Oct;48(4):1312-27

  431. Local Ablative Therapies in HCC: Percutaneous Ethanol Injection and Radiofrequency Ablation
    Mahnken A, Bruners P, Gunther R. Dig Dis 2009;27:148-156

  432. Early Three-Dimensional Conformal Radiotherapy for Patients With Unresectable Hepatocellular Carcinoma After Incomplete Transcatheter Arterial Chemoembolization: A Prospective Evaluation of Efficacy and Toxicity
    Oh D, Lim DH, Park HC, Paik SC, Koh KC, Lee JH, Choi MS, Yoo BC, Lim HK, Lee WJ, Rhim H, Shin SW, Park KB. Am J Clin Oncol. 2010 Feb 5. [Epub ahead of print]

  433. Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapie
    Olsen, S., Brown R, Siegel A. Therapeutic Advances in Gastroenterology, Vol. 3, No. 1, 55-66

  434. In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score
    Simons JP, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. Cancer. 2010 Feb 8. [Epub ahead of print]

  435. A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
    Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. Clin Gastroenterol Hepatol. 2009 Nov 27. [Epub ahead of print]

  436. What are the implications of the spontaneous spleno-renal shunts in liver cirrhosis?
    Tarantino G, Citro V, Conca P, Riccio A, Tarantino M, Capone D, Cirillo M, Lobello R, Iaccarino V. BMC Gastroenterol. 2009 Nov 24;9:89

  437. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy
    Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Annu Rev Med. 2010;61:317-28

  438. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Oncologist. 2010;15(1):85-92. Epub 2010 Jan 5

  439. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety
    Vitale A, Volk M, Pastorelli D et al. AASLD 2009

  440. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma
    Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V, Lim E, Hershman DL, Brown RS Jr, Siegel AB. Cancer. 2010 Feb 8. [Epub ahead of print]

  441. Clinical management of hepatitis B virus infection correlated with liver transplantation
    Zhang J, Zhou L, Zheng SS. Hepatobiliary Pancreat Dis Int. 2010 Feb;9(1):15-21.

  442. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study
    Zhao JD, Liu J, Ren ZG, Gu K, Zhou ZH, Li WT, Chen Z, Xu ZY, Liu LM, Jiang GL. Radiat Oncol. 2010 Feb 12;5(1):12. [Epub ahead of print]

  443. Both the 5th and 6th editions of TNM staging system fail to independently predict long-term prognosis after radical hepatectomy in hepatocellular carcinoma sized > or = 5 cm
    Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Chin Med Sci J. 2009 Dec;24(4):220-6.

  444. Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy
    Imai K, Beppu T, Nakayama Y, Ishiko T, Horino K, Komori H, Masuda T, Hayashi H, Okabe H, Baba Y, Watanabe M, Takamori H, Awai K, Yamashita Y, Baba H. J Surg Oncol 2009 Apr 28 (Epub ahead of print)

  445. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States
    Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Hepatology 2008;49:1563-1570.

  446. Hepatocellular carcinoma in patients with cryptogenic cirrhosis
    Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group. Clinical Gastroenterol Hepatol. 2009;7:580-5.

  447. Surgery of hepatocellular carcinoma complicated with cancer thrombi in bile duct: efficacy for criteria for different therapy modalities
    Xiangji L, Weifeng T, Bin Y, Chen L, Xiaoqing J, Baihe Z, Feng S, Mengchao W. Langenbecks Arch Surg. 2009 may 7. (Epub ahead of print)

  448. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status
    Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS; Liver Cancer Network. Am J Gastroenterol 2003;9:2060-3.

  449. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis
    Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G,Plank C, Peck Radosavljevic M. Oncologist 2009;14(1):70-6.

  450. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
    Thomas M, Morris J, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, and Abbruzzese J. J Clin Oncol 2009;27(6):843-850.

  451. The burden of illness associated with hepatocellular carcinoma in the United States
    Lang K, Danchenko N, Gondek K, et al. J Hepatol 2009;50:89-99.

  452. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B
    Yuen M, Tanaka Y, Fong D, et al. J Hepatol 2009;50:80-88.

  453. Novel Advancements in the management of hepatocellular carcinoma in 2008
    LLovet J, Bruix J. J Hepatol 2008;48:S20-S37.

  454. Increased Risk of Hepatocellular Carcinoma Among Patients with Hepatitis C Cirrhosis and Diabetes Mellitus
    Veldt B, Chen W, Heathcote J, Wedemeyer H, Reichen J, Hoffmann W, de Knegt R, Zeuzem S, Manns M, Hansen B, Schalm S, and Janssen H. HEPATOLOGY 2008;47:1856-1862.

  455. Diagnosis and Treatment of Hepatocellular Carcinoma
    El-Serag H, Marrero J, Rudolph L, and Reddy K. Gastroenterology 2008;134:1752-1763.

  456. Sorafenib in Advanced Hepatocellular Carcinoma
    Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, de Oliveira A, Santoro A, Raoul J, Former A, Schwartz M, Porta C, Zeuzem, Bolondi L, Greten T, Galle P, Seitz J, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, and Bruix J for the SHARP Investigators Study Group. N Engl J Med 2008;359:378-90.

  457. Sorafenib in Liver Cancer-Just the Beginning
    Roberts LR. N Engl J Med 2008;359:420-422.
   

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2011 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource
for US healthcare providers only. Use of this Web site is governed by the CLD Foundation terms of use and privacy statement.